open access

Vol 10, No 3 (2015)
Review Papers
Published online: 2015-07-08
Get Citation

PCSK9 inhibitors — a new lipid-lowering therapy

Kamil Janikowski, Małgorzata Lelonek
Folia Cardiologica 2015;10(3):178-182.

open access

Vol 10, No 3 (2015)
Review Papers
Published online: 2015-07-08

Abstract

One of the elements of the primary and secondary prevention of cardiovascular disease is the use of lipid-lowering therapy in patients with hypercholesterolaemia. The use of statins does not always bring the desired effect and some adverse effects occur among 5–20% patients. A new alternative may be PCSK9 inhibitors biological therapy. In this article we present results of the newest trials concerning PCSK9 inhibitors, evolocumab and alirocumab.

Abstract

One of the elements of the primary and secondary prevention of cardiovascular disease is the use of lipid-lowering therapy in patients with hypercholesterolaemia. The use of statins does not always bring the desired effect and some adverse effects occur among 5–20% patients. A new alternative may be PCSK9 inhibitors biological therapy. In this article we present results of the newest trials concerning PCSK9 inhibitors, evolocumab and alirocumab.

Get Citation

Keywords

PCSK9 inhibitors, evolocumab, alirocumab

About this article
Title

PCSK9 inhibitors — a new lipid-lowering therapy

Journal

Folia Cardiologica

Issue

Vol 10, No 3 (2015)

Pages

178-182

Published online

2015-07-08

Bibliographic record

Folia Cardiologica 2015;10(3):178-182.

Keywords

PCSK9 inhibitors
evolocumab
alirocumab

Authors

Kamil Janikowski
Małgorzata Lelonek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl